Cedric Francois, co-founder and CEO of Apellis, discusses the recent FDA approval of the PNH therapy Empaveli, what advantages it may provide over existing therapies, and other indications the company will pursue for this medicine.

A New Therapy Offers A Different Approach to Inhibiting the Complement System

<p>RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy. </p>

Business

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Share A New Therapy Offers A Different Approach to Inhibiting the Complement System

Sign up to save your podcasts

A New Therapy Offers A Different Approach to Inhibiting the Complement System

A New Therapy Offers A Different Approach to Inhibiting the Complement System